1. Home
  2. RTB vs MXCT Comparison

RTB vs MXCT Comparison

Compare RTB & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RTB

RTB Digital Inc. Common Stock

HOLD

Current Price

$8.00

Market Cap

128.6M

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$0.99

Market Cap

136.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RTB
MXCT
Founded
2022
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.6M
136.2M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
RTB
MXCT
Price
$8.00
$0.99
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $4.11
AVG Volume (30 Days)
124.3K
★ 334.5K
Earning Date
11-19-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$11,131,000.00
★ $33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.24
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.83
$0.64
52 Week High
$20.75
$1.86

Technical Indicators

Market Signals
Indicator
RTB
MXCT
Relative Strength Index (RSI) 37.30 27.85
Support Level $8.00 $0.98
Resistance Level $11.40 $1.27
Average True Range (ATR) 0.97 0.05
MACD 0.08 -0.01
Stochastic Oscillator 10.83 9.73

Price Performance

Historical Comparison
RTB
MXCT

About RTB RTB Digital Inc. Common Stock

RTB Digital Inc is focused on developing and operating a professional SaaS (Software as a Service) platform that hosts an exclusive coalition of professionally managed online media channels. Its operations include software development, advertising and sponsorship sales, and onboarding third-party content operators (Platform Partners) to publish content on the platform.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: